Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial
EMMAUS LIFE SCIENCES INC (EMMA)
Company Research
Source: GlobeNewswire
TORRANCE, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the top-line preliminary results in the first patient in the company’s Pilot/Phase 1 study in the treatment of diverticulosis. The study is utilizing the same pharmaceutical-grade L-glutamine (PGLG) oral powder used in Endari® to evaluate the change in the number, shape and size of colonic diverticula and assess safety. The first patient had a colonoscopy at the start of the study and another colonoscopy after six months of taking 15 grams of PGLG twice a day. While the results in the first patient are preliminary only, the Principal Investigator (PI) observed “A marginal but decreased size in some of the diverticula compared to the baseline.” The PI also added that, “In addition, there appears to be smoothing of the edges at the opening of the diverticula compared to the baseline, suggestive of a healing process.” Clinically, the
Show less
Read more
Impact Snapshot
Event Time:
EMMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EMMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EMMA alerts
High impacting EMMAUS LIFE SCIENCES INC news events
Weekly update
A roundup of the hottest topics
EMMA
Sec Filings
- 4/1/24 - Form NT
- 2/29/24 - Form 4
- 2/26/24 - Form 8-K
- EMMA's page on the SEC website